Stock events for Nuvalent, Inc. (NUVL)
Several events have impacted Nuvalent, Inc.'s stock price in the past six months. The company reported an EPS of -$1.70 in Q3 2025. The FDA accepted Nuvalent's New Drug Application for zidesamtinib, with a PDUFA target action date of September 18, 2026. Several analysts have maintained or increased price targets and recommendations for NUVL. Nuvalent reported its Q4 2025 earnings, with an actual EPS of -$1.58, missing the consensus estimate. A biotech fund reportedly sold $84 million of Nuvalent stock. Over the past 90 days, there has been a significant net selling trend by insiders. The stock has shown a 1-year total shareholder return of 43.5%.
Demand Seasonality affecting Nuvalent, Inc.’s stock price
Nuvalent, Inc. does not currently have commercialized products that would be subject to typical demand seasonality. The company's revenue is not generated from product sales but rather from funding and collaborations to advance its drug candidates through clinical trials. Therefore, demand seasonality for its products and services is not applicable at this stage of its business.
Overview of Nuvalent, Inc.’s business
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for cancer, operating within the Healthcare sector and Biotechnology industry. The company focuses on precision oncology, targeting kinase alterations that drive tumor growth, and uses its expertise in chemistry and structure-based drug design to create small molecule inhibitors. Its major product candidates include NVL-520 (zidesamtinib), a brain-penetrant ROS1-selective inhibitor; NVL-655 (neladalkib), a brain-penetrant ALK-selective inhibitor; and NVL-330, a brain-penetrant HER2-selective inhibitor.
NUVL’s Geographic footprint
Nuvalent, Inc. is headquartered in Cambridge, Massachusetts, United States, and conducts global clinical development. Its lead product candidates are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with all of its operations primarily in the United States.
NUVL Corporate Image Assessment
Nuvalent's brand reputation appears to be largely positive, driven by its scientific advancements and pipeline progress in precision oncology. The company has consistently announced pipeline progress and anticipated milestones, including the FDA acceptance of the NDA for zidesamtinib. Analyst coverage is overwhelmingly positive, and Nuvalent has participated in several healthcare conferences. The reported net selling trend by insiders could potentially raise questions among some investors. Overall, Nuvalent is perceived as a high-potential, clinical-stage biotech firm with a strong focus on addressing unmet medical needs in cancer.
Ownership
Nuvalent, Inc. has significant institutional ownership, with 427 institutional owners and shareholders holding a total of 83,485,569 shares, representing approximately 97.26% of the stock. Major institutional owners include Deerfield Management Company, L.P., FMR LLC, The Vanguard Group, Inc., and BlackRock, Inc. The largest individual Nuvalent shareholder is James E. Flynn, owning 17.90 million shares, representing 22.77% of the company. Insiders collectively hold about 2.84% to 10.20% of the stock.
